Drug Trial Radar · NCT04408638
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Feb 23, 2021
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.
Conditions
- Diffuse Large B-cell Lymphoma
Interventions
ObinutuzumabDrug
Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
GlofitamabDrug
Participants will receive IV glofitamab for up to 12 cycles.
RituxumabDrug
Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
TocilizumabDrug
Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
GemcitabineDrug
Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
OxaliplatinDrug
Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS), defined as the time from randomization to date of death from any causeTime frame: Up to 5 years
Locations
63 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Community Cancer Institute (CCI)
Fresno, California
Baptist - MD Anderson Cancer Center
Jacksonville, Florida
University of Maryland Medical Center
Baltimore, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Mississippi Medical Center
Jackson, Mississippi
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Icahn School of Medicine at Mount Sinai
New York, New York
Duke University Medical Center
Durham, North Carolina
Prince of Wales Hospital
Randwick, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Monash Health Monash Medical Centre
Clayton, Victoria, Australia
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
UZ Leuven Gasthuisberg
Leuven, Belgium
CHU de Liège (Sart Tilman)
Liège, Belgium
Peking University Third Hospital
Beijing, China
Sun Yet-sen University Cancer Center
Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Fudan University Shanghai Cancer Center
Shanghai, China
Tianjin Cancer Hospital
Tianjin, China
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Zhejiang Cancer Hospital
Zhejiang, China
Henan Cancer Hospital
Zhengzhou, China
Aarhus Universitetshospital Skejby
Aarhus N, Denmark
Rigshospitalet
København Ø, Denmark
Institut Bergonie
Bordeaux, France
Hopital Henri Mondor
Créteil, France
Hopital Claude Huriez
Lille, France
Chu de Montpellier-St Eloi
Montpellier, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
CHU Pontchaillou
Rennes, France
Universitatsklinikum Frankfurt
Frankfurt, Germany
Universitätsklinikum Gießen und Marburg GmbH Standort Gießen Medizinische Klinik I
Giessen, Germany
Universitaetsklinikum Regensburg
Regensburg, Germany
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli
Lublin, Poland
Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie
Olsztyn, Poland
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.